The use of rifamycins is limited by drug interactions in human immunodeficiency virus (HIV)-infected persons
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Drug-Drug Interactions in Inmates Treated for Human Immunodeficiency Virus and Mycobacterium tuberculosis
Infection or Disease: An Institutional Tuberculosis Outbreak progression from primary TB infection and an increased rate of reactivation [2, 3] . The host response to M. tuberculosis enhances HIV replication, which accelerates the progression of HIV disease [1] . The use of HAART has reduced morbidity and mortality in HIV-infected patients [4, 5] . However, the use of HAART for patients with TB is complicated by drug interactions between the rifamycins, the most important class of antituberculosis drugs, and both protease inhibitors (PIs) and nonnucleoside reverse-transcriptase inhibitors (NNRTIs) [6] [7] [8] . Guidelines have been issued with recommendations for the concurrent treatment of HIV and TB [1] . Drug interactions between rifamycins and PIs and NNRTIs (referred to as "drug-drug" interactions) are attributable to induction or inhibition of the cyto- chrome P450 (CYP) isoenzymes, which are involved in the metabolism of rifamycins, PIs, and NNRTIs [1, 6, 9] . Rifamycins induce CYP3A, which leads to decreased blood concentrations of PIs and NNRTIs, reducing their therapeutic effect. Rifabutin, which is a less potent inducer of CYP3A than are other rifamycins, is an alternative to rifampin, if used with PIs or NNRTIs [1, 9] . However, PIs and NNRTIs also may inhibit or induce CYP3A. As inhibitors of CYP3A4, PIs and delavirdine may increase rifabutin concentrations, potentially increasing the likelihood of toxic events. Efavirenz and nevirapine, in contrast, induce CYP3A4 and may reduce rifabutin concentrations. Because rifampin and rifapentine are not substrates for CYP3A4, concentrations of these 2 rifamycins are not thought to change during the coadministration of PIs and NNRTIs (C.A.P., unpublished observation). Existing guidelines have suggested the substitution of rifabutin for rifampin when coadministered with PIs and NNRTIs, although this has not been extensively studied [1] . A recent pharmacokinetic study in HIV-seropositive patients without mycobacterial infection showed that rifabutin at a dosage of either 300 mg every 7 days or 150 mg every 3 days was safe as concurrent therapy with ritonavir and saquinavir [10] . Another recent report noted successful short-term outcomes for the treatment of TB in HIV-infected patients receiving both rifabutin and PI-containing HAART [11] . During an outbreak of drug-susceptible TB among HIV-infected male inmates at a prison [12] , rifabutincontaining regimens for the treatment of latent TB infection (LTBI) and TB disease were used in persons receiving PI and/or NNRTI-containing HAART. We report on the impact of coadministration of rifabutin and HAART on rifabutin drug concentrations, drug toxicity, and clinical outcomes.
PATIENTS AND METHODS
Study population and clinical intervention.
An outbreak of TB was recognized in September 1999 in 1 of 3 HIV-dedicated dormitories at a state prison [12] . A total of 323 HIV-infected inmates were exposed to the source case patient. In addition to the source case patient, 30 other inmates were diagnosed with TB during the next 4 months. The investigation also revealed a high proportion of tuberculin skin test (TST) conversions (defined as an increase of у5 mm in the diameter of the induration, compared with a TST result performed within the previous year) among inmates from the side of the dormitory in which the source patient lived (71%). Because all inmates in the dormitory were HIV-infected and at high risk for developing TB disease if infected with M. tuberculosis, all exposed inmates were considered to be recently infected with M. tuberculosis, regardless of previous or current TST reactivity. All exposed inmates for whom the diagnosis of TB disease was excluded began to receive a 2-month course of rifabutinpyrazinamide for presumed LTBI, regardless of whether they were receiving HAART. Inmates with TB disease who were receiving antiretroviral therapy had rifabutin substituted for rifampin. We defined HAART as a regimen that included either 3 nucleoside reverse-transcriptase inhibitors (NRTIs), including abacavir, or у1 NRTIs plus a PI or an NNRTI (efavirenz was the sole NNRTI used). Treatment of patients with TB disease or infection began in September 1999 and was directly observed and dispensed daily by prison nurses.
Rifabutin dosages were adjusted according to Centers for Disease Control (CDC) guidelines available at the time [1] . In the case of drug combinations for which there were no existing guidelines, dosages were determined by consensus opinion of experts from academia and the CDC who had developed the existing guidelines. Drug combinations and adjusted dosages of rifabutin, PIs, and NNRTIs are listed in table 1 and table 2 . Patients were classified into 1 of 3 groups according to the drugs being administered and their potential interactions: (1) the noninteracting HAART group (patients receiving no antiretrovirals or NRTIs only), (2) the single-interacting HAART group (patients receiving either 1 PI or the NNRTI efavirenz), or (3) the multi-interacting HAART group (patients receiving either 2 PIs or у1 PI with efavirenz).
Patients were evaluated before treatment and at 30 and 60 days after the start of therapy by determination of complete blood and platelet counts and serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin, uric acid, and glucose levels. All patients were educated about potential adverse effects and were screened monthly for signs and symptoms of TB disease and adverse events.
Pharmacokinetic evaluation. Of 238 HIV-infected patients receiving rifabutin-containing treatment, 123 (52%) underwent steady-state therapeutic drug monitoring (TDM) for serum rifabutin concentrations at either day 30 or day 60 of treatment. For all patients receiving either multiple-inter- acting or single-interacting HAART, rifabutin concentrations were determined; concentrations also were determined in a subgroup receiving noninteracting HAART. Blood samples for determination of the peak serum rifabutin concentration were obtained 3-4 h after the observed administration of a dose and were promptly centrifuged; the serum samples were transferred into polypropylene tubes and shipped on dry ice to either the National Jewish Medical and Research Center (NJMRC) or Ottawa General Hospital (OGH). Rifabutin concentrations were measured by high-performance capillary electrophoresis (HPCE) or high-performance liquid chromatography (HPLC) [10, 13] . The HPCE assay was crossvalidated against 2 HPLC methods at NJMRC and OGH; all 3 methods produced similar results. The HPCE values fell below the HPLC values by 6% (18% SD) for 23 clinical samples tested in the cross-validation. For rifabutin regimens of 300 or 450 mg once daily, the normal range for peak serum concentrations is 0.3-0.8 mg/mL [13] [14] [15] [16] [17] . On the basis of recommendations by experts, rifabutin concentrations of !0.1 mg/mL were considered to be significantly low and considered a threshold at which intervention was warranted.
Statistical analyses.
We performed stratified analyses comparing rifabutin concentrations and hepatotoxity during treatment in the 3-drug groups. Statistical differences were determined using the x 2 test for trend and the 2-tailed Student's t test, as appropriate. To determine the independent effect of drug regimen on rifabutin concentration, we performed forward stepwise multivariate logistic-regression analysis. On the basis of univariate analysis, we determined that potential confounders included age, CD4 ϩ T lymphocyte count, virus load, and rifabutin dosage. Data were analyzed by use of Epi Info version 6.04d [18] and SAS version 6.12 (SAS Institute).
RESULTS
Study population and clinical intervention.
Between 1 September and 15 October 1999, 238 inmate patients began rifabutin-containing therapy; 225 men were receiving a 2-month course rifabutin and pyrazinamide for LTBI, and 13 men were receiving a rifabutin-containing regimen as treatment for TB disease. The median age of patients was 36.9 years (range, 20.5-54.3 years). All patients were male; 208 were black, 20 were white, and 1 was Hispanic. Age and race information were unavailable for 9 patients. All inmate patients were HIVinfected except 3, who were treated simultaneously at the prison for LTBI but were not associated with the TB outbreak. Of the 225 men receiving treatment for LTBI, 129 (57%) were receiving HAART. On the basis of rifamycin-HAART interactions, 29 men (23%) were classified as receiving noninteracting HAART, 75 (58%) as receiving single-interacting HAART, and 25 (19%) as receiving multi-interacting HAART. Of the 13 patients being treated with rifabutin-containing regimens for TB disease, 3 (23%) were receiving noninteracting HAART, 6 (46%) were receiving single-interacting HAART, and 4 (31%) were receiving multi-interacting HAART. Before pharmacological monitoring, 88 (37%) of 238 rifabutin dosages and 47 (84%) of 56 PI dosages were adjusted according to current guidelines or consensus expert opinion; all patients with dosage adjustments were receiving either single-interacting or multi-interacting HAART. The standard oral rifabutin dosage is 300 mg/day; the dosage in these groups ranged from 150 mg twice a week to 450 mg/day. Of the 225 patients who began a 2-month course of rifabutinpyrazinamide for LTBI, 158 (70%) completed directly observed treatment while incarcerated; 19 (8%) were released from prison before the completion of treatment. After steady-state peak serum rifabutin concentrations were determined, 11 patients (5%) had their treatment changed to a 9-month course of isoniazid, because their serum rifabutin concentration was !0.1 mg/mL. After a TB educational session was delivered to inmates, 13 patients (6%) with LTBI admitted that they had not adhered to the regimen, despite administration of doses under direct observation (i.e., the patients placed the medication inside the cheek or under the tongue and later discarded it). Rifabutin-pyrazinamide was discontinued for 24 patients (11%) with adverse events (table 3), including 18 men (8% of total) with serum aminotransferase concentrations 15 times the upper limits of normal (AST range, 205-2053 U/L; ALT range, 58-1048 U/L; total bilirubin, 0.5-14.8 mg/dL). Two men required hospitalization for hyperbilirubinemia and elevated serum aminotransferase concentrations; all 18 men recovered. Nine (50%) of these men demonstrated the presence of antibodies to hepatitis C virus on serological testing. Six (33%) of 18 were receiving HAART. There was no association between HAART regimens and hepatotoxicity ( ). Six of 24 pa-P p .17 tients with adverse events had rifabutin concentrations determined, and none had peak serum rifabutin concentrations above the normal range.
Of the 13 men with TB disease who were treated with a rifabutin-containing regimen, 7 (54%) completed treatment while incarcerated. Five (38%) were released from prison before com- pleting treatment and were treated thereafter at local health departments. One man (8%) who was receiving multi-interacting HAART (ritonavir, saquinavir, and stavudine) had an AST level of 372 U/L after 6 weeks of treatment. At that time, his rifabutin concentration was 0.07 mg/mL. Pyrazinamide therapy discontinued, and the rifabutin dosage was increased from 150 mg twice a week to 300 mg twice a week. No subsequent rifabutin concentrations were determined, and the patient completed treatment, with improvement of the serum aminotransferase levels. In addition, he had a positive serological test for hepatitis C.
Three men treated for LTBI developed TB disease within 4 months after starting therapy. One man did not complete LTBI treatment because of hepatotoxicity and developed culturepositive TB 2 months later. The second man later admitted to nonadherence; symptoms developed, and radiography revealed changes consistent with TB. Sputum cultures were negative; however, he responded to antituberculosis therapy. The third patient claimed adherence to treatment and had a rifabutin concentration in the normal range (0.32 mg/mL). Three months after the completion of treatment, he developed symptoms of TB. Although sputum cultures were negative, findings of chest radiography were consistent with TB, and the patient responded to antituberculosis treatment. Two additional men who received rifabutin-pyrazinamide during fall 1999 developed sputum culture-positive TB disease during spring 2001. One had a rifabutin concentration of 0.22 mg/mL; the other inmate did not have a rifabutin concentration performed. DNA fingerprints of isolates from both patients matched those of all other outbreakassociated case patients (20) with culture-positive disease.
Pharmacokinetic evaluation. Steady-state peak rifabutin concentrations were determined for 123 patients: 35 receiving noninteracting HAART, 67 receiving single-interacting HAART, and 21 receiving multi-interacting HAART. Rifabutin concentrations ranged 0-0.92 mg/mL. The median rifabutin concentrations were 0.20 mg/mL in the noninteracting HAART group (range, 0-0.92), 0.26 mg/mL in the single-interacting HAART group (range, 0-0.90), and 0.23 mg/mL in the multi-interacting HAART group (range, 0-0.67). The proportion of patients with steady-state peak serum rifabutin concentrations of !0.1 mg/ mL differed significantly among the 3 groups: 3 (9%) of 35 patients receiving noninteracting HAART, 13 (19%) of 67 patients receiving single-interacting HAART, and 6 (29%) of 21 patients receiving multi-interacting HAART ( ; x 2 test P p .05 for trend; table 4). The presence of diarrhea or malabsorption was not noted in the medical record of any inmate for whom a rifabutin concentration was determined. The association between HAART regimen and low rifabutin concentration held in a separate analysis that excluded patients who later admitted nonadherence to rifabutin-containing therapy ( ; x 2 test P p .04 for trend). Table 5 further stratifies the 3 HAART groups by the specific antiretroviral agent used and illustrates that low rifabutin concentrations occurred even among recipients who received the highest dosage of rifabutin (450 mg/day in combination with efavirenz). In the multivariate model, only the use of a rifabutin dosage of 150 mg twice per week (used with ritonavir-containing HAART) was associated with a peak serum rifabutin concentration of !0.1 mg/mL ( ). P p .03
DISCUSSION
This report of an outbreak of TB among HIV-infected inmates is, to our knowledge, the first that involved widespread institutional administration of rifamycin-containing antituberculosis regimens with HAART containing PIs and NNRTIs. It provided an opportunity to prevent additional cases of TB but required the use of drug combinations for which prescribing guidelines were not clearly determined. Of particular note was the large proportion of TST conversions that occurred, despite reports elsewhere of cutaneous anergy associated with HIV [19] . To optimize the management of patients, we consulted experts in the management of TB and HIV. Although the precise value of TDM in the treatment of TB is still under debate [20] , dosage adjustments were deemed to be necessary for persons with serum drug concentrations significantly lower than the normal range.
During this outbreak, TDM allowed for the identification of patients who were receiving treatment for LTBI who had low serum rifabutin concentrations-these patients were subsequently treated with isoniazid. Whether the low concentrations were attributable to drug interactions, malabsorption, nonadherence, or simply to low dosage could not be determined. However, none of these patients developed TB disease later, after isoniazid therapy. The use of TDM did not predict the likelihood of drug-related adverse events or LTBI treatment failure; only 2 patients had rifabutin concentrations above the normal range, and both completed treatment without incident.
Given the number of dosage adjustments required to treat patients with TB and LTBI, one option was to treat those with LTBI with a 9-month course of isoniazid rather than with a 2-month course of rifabutin-pyrazinamide, which eliminated the need for dosage adjustments. However, a major source of concern was the rate at which inmates were released from confinement; during the outbreak, an average of 9 men per month were released, and inmates were released regardless of whether they were undergoing treatment. Because inmates with LTBI were considered to be at extraordinary risk of developing TB, health officials opted to treat them as expeditiously as possible, to ensure completion of treatment. However, the complexity of the regimens led to difficulties in defining the optimal dosages of both rifabutin and of selected antiretroviral agents. Given the current complexities and wider availability of HAART in areas of the world where TB is endemic, there is a need for the refinement of treatment guidelines, as well as education of clinicians with regard to potential drug-drug interactions.
Stratification of patients receiving rifabutin according to HAART regimen revealed an association between the complexity of the regimen and the likelihood of having a rifabutin concentration of !0.1 mg/mL. In the multivariate model, only a rifabutin dosage of 150 mg twice per week used with ritonavir-containing HAART was associated with a low serum rifabutin concentration. At the prison, ritonavir always was used to enhance the concentration of a second PI. Given the results of our experience, it may be prudent to use a higher dosage of rifabutin for patients taking low-dose, ritonavircontaining HAART. We also considered the possibility that low serum rifabutin concentrations could have resulted from concomitant administration of didanosine [21] . However, of the 29 men taking didanosine, only 2 had rifabutin concentrations of !0.1 mg/mL, although neither had received didanosine on the morning that blood was drawn for determination of the concentration. We cannot comment on the clinical implications of low serum concentrations of rifabutin in the treatment of LTBI, because all men with low concentrations had their therapy switched to isoniazid. More notably, 2 of 5 patients treated for LTBI who later developed TB disease had rifabutin concentrations at day 30 that were in the normal range. Patients with TB disease and low rifabutin concentrations subsequently had their rifabutin dosage increased, and all successfully completed treatment.
Our assessment was observational rather than controlled and was undertaken during an outbreak and involved many logistical challenges. Only slightly more than half the patients had serum rifabutin concentrations determined, and priority was given to those patients for whom a serious drug-drug interaction was likely. For this reason, the number of patients receiving noninteracting HAART for whom serum concentrations were determined was minimal, compared with the numbers of patients in the other groups for whom concentrations were determined. Similarly, we were not able to assess the association between hepatitis C virus infection and development of hepatotoxicity, because serological tests for hepatitis C virus were not performed for men without hepatotoxicity [22] [23] [24] .
It may be debatable whether there is a trend of increasing complexity of HIV treatment regimen as more drugs with CYP3A interactions (either inhibitory or inducing) are added to a particular HAART regimen. We propose that it is likely that the use of several CYP3A inducers or inhibitors in the regimen will have an unpredictable impact on the metabolism of rifamycins and on serum drug concentrations for patients receiving the concurrent treatment of TB disease or LTBI.
Despite existing guidelines and the recommendations of experts in the treatment of TB and HIV, the rifabutin concentrations that were determined were highly unpredictable, re-gardless of the rifabutin dosage. As new antiretroviral agents are developed and included in already complex regimens, it will be important to update dosage guidelines for the concurrent use of rifamycins. In such circumstances, TDM may have some benefit in identifying patients with very low serum rifamycin concentrations. As illustrated here, however, a serum drug concentration in the normal range may not ensure the effectiveness of the drug in the treatment of LTBI.
Our experience suggests that expanded research to enhance current recommendations is needed to guide clinicians in the concurrent use of rifamycins for patients receiving PI-containing or NNRTI-containing HAART. As the use of HAART expands in Asia and sub-Saharan Africa, where TB is endemic, there will be a substantial increase in the number of persons receiving HAART and concurrent antituberculosis therapy. Because rifamycin-containing regimens are preferred for treatment of TB, especially for HIV-infected persons, drug-drug interactions between antiretroviral medications and rifamycins will remain important [25] [26] [27] [28] [29] [30] . To manage these patients optimally, further understanding of the impact of these drug-drug interactions is needed.
